Dimiter S. Dimitrov, Ph.D.
Dimiter S. Dimitrov, Ph.D.
Senior Investigator
Head, Protein Interaction Group

Dr. Dimitrov and his research group are experts in display/screening/libraries methodologies, antibody engineering, and protein biochemistry, structural biology and computational biology as well as virology, immunology and cancer biology. His major long-term goal is the development of clinically useful therapeutics and vaccines against cancer, HIV-1 and emerging and biodefense-related viruses as well as other related diseases including immune disorders. The biological therapeutics and vaccines are based on human monoclonal antibodies in several formats including full size antibodies typically IgG1s, engineered antibody domains (eAds), chimeric antigen receptors (CARs), bispecific and multispecific antibodies, antibody-drug conjugates (ADCs), bi-specific T-cell engagers (BiTEs) and bi-specific killer-cell engagers (BiKEs).

Areas of Expertise
1) antibodies 2) vaccines 3) therapeutic proteins 4) protein engineering 5) phage and yeast display 6) drugability

Contact Info

Dimiter S. Dimitrov, Ph.D.
Center for Cancer Research
National Cancer Institute
Building 567, Room 152
Frederick, MD 21702-1201
301-846-1352
dimiter.dimitrov@nih.gov

Protein Interactions

Protein interactions are important for understanding of biological function, and for prevention, diagnosis and treatment of diseases. Our research focuses on antibody-antigen and ligand-receptor interactions. We identify novel human monoclonal antibodies, characterize and improve their properties, elucidate their mechanisms of interactions, investigate antibody-mediated modulation of ligand-receptor interactions, and apply the knowledge gained to solve biomedical problems. Our major long-term goal is to develop antibody-based therapeutics including engineered antibody domains and antibody-guided nanoparticles against cancer and other diseases. Currently, we identify, engineer and characterize antibodies against components of the insulin-like growth factor (IGF) system and other cancer-related proteins, HIV, and emerging and biodefense-related microbes including Nipah and Hendra viruses, and dengue virus. We also study mechanisms of antibody elicitation and proposed a new (germline/maturation) concept with implications for development of vaccines against AIDS and other diseases.

Scientific Focus Areas:
Biomedical Engineering and Biophysics, Computational Biology, Immunology, Molecular Pharmacology, Virology
Selected Recent Publications
  1. Chen W, Gong R, Ying T, Prabakaran P, Zhu Z, Feng Y, Dimitrov DS.
    Curr Drug Discov Technol. 11: 28-40, 2014. [ Journal Article ]
  2. Chen W, Feng Y, Prabakaran P, Ying T, Wang Y, Sun J, Macedo CD, Zhu Z, He Y, Polonis VR, Dimitrov DS.
    J Virol. 88: 1125-39, 2014. [ Journal Article ]
  3. Sun JY, Shen J, Thibodeaux J, Huang G, Wang Y, Gao J, Low PS, Dimitrov DS, Sumer BD.
    Laryngoscope. 124: E312-9, 2014. [ Journal Article ]
  4. Ofek G, Zirkle B, Yang Y, Zhu Z, McKee K, Zhang B, Chuang GY, Georgiev IS, O'Dell S, Doria-Rose N, Mascola JR, Dimitrov DS, Kwong PD.
    J Virol. 88: 2426-41, 2014. [ Journal Article ]
  5. Tang Z, Feng M, Gao W, Phung Y, Chen W, Chaudhary A, Croix BS, Qian M, Dimitrov DS, Ho M.
    Mol Cancer Ther. 12: 416-26, 2013. [ Journal Article ]

Dr. Dimitrov obtained his Ph.D. in chemistry at the University of Sofia, and his Sc.D. in biology at the Bulgarian Academy of Sciences, where he was elected as a Professor of Biophysics. He was appointed to the Senior Biomedical Research Service at NIH and selected as an NCI outstanding mentor. His research focuses on development of human monoclonal antibodies including isolated engineered antibody domains for prevention and treatment of cancer and other diseases.

Name Position
Weizao Chen Ph.D. Staff Scientist
Yang Feng Ph.D. Research Biologist
Dontcho Jelev Ph.D. Research Collaborator
Wei Li Postdoctoral Fellow (Visiting)
John Owens Special Volunteer
Yanping Wang Research Collaborator
Tianlei Ying Ph.D. Postdoctoral Fellow (Visiting)
Zhongyu Zhu, Ph.D. Staff Scientist

Research

Protein Interactions

Protein interactions are important for understanding of biological function, and for prevention, diagnosis and treatment of diseases. Our research focuses on antibody-antigen and ligand-receptor interactions. We identify novel human monoclonal antibodies, characterize and improve their properties, elucidate their mechanisms of interactions, investigate antibody-mediated modulation of ligand-receptor interactions, and apply the knowledge gained to solve biomedical problems. Our major long-term goal is to develop antibody-based therapeutics including engineered antibody domains and antibody-guided nanoparticles against cancer and other diseases. Currently, we identify, engineer and characterize antibodies against components of the insulin-like growth factor (IGF) system and other cancer-related proteins, HIV, and emerging and biodefense-related microbes including Nipah and Hendra viruses, and dengue virus. We also study mechanisms of antibody elicitation and proposed a new (germline/maturation) concept with implications for development of vaccines against AIDS and other diseases.

Scientific Focus Areas:
Biomedical Engineering and Biophysics, Computational Biology, Immunology, Molecular Pharmacology, Virology

Publications

Selected Recent Publications
  1. Chen W, Gong R, Ying T, Prabakaran P, Zhu Z, Feng Y, Dimitrov DS.
    Curr Drug Discov Technol. 11: 28-40, 2014. [ Journal Article ]
  2. Chen W, Feng Y, Prabakaran P, Ying T, Wang Y, Sun J, Macedo CD, Zhu Z, He Y, Polonis VR, Dimitrov DS.
    J Virol. 88: 1125-39, 2014. [ Journal Article ]
  3. Sun JY, Shen J, Thibodeaux J, Huang G, Wang Y, Gao J, Low PS, Dimitrov DS, Sumer BD.
    Laryngoscope. 124: E312-9, 2014. [ Journal Article ]
  4. Ofek G, Zirkle B, Yang Y, Zhu Z, McKee K, Zhang B, Chuang GY, Georgiev IS, O'Dell S, Doria-Rose N, Mascola JR, Dimitrov DS, Kwong PD.
    J Virol. 88: 2426-41, 2014. [ Journal Article ]
  5. Tang Z, Feng M, Gao W, Phung Y, Chen W, Chaudhary A, Croix BS, Qian M, Dimitrov DS, Ho M.
    Mol Cancer Ther. 12: 416-26, 2013. [ Journal Article ]

Biography

Dr. Dimitrov obtained his Ph.D. in chemistry at the University of Sofia, and his Sc.D. in biology at the Bulgarian Academy of Sciences, where he was elected as a Professor of Biophysics. He was appointed to the Senior Biomedical Research Service at NIH and selected as an NCI outstanding mentor. His research focuses on development of human monoclonal antibodies including isolated engineered antibody domains for prevention and treatment of cancer and other diseases.

Team

Name Position
Weizao Chen Ph.D. Staff Scientist
Yang Feng Ph.D. Research Biologist
Dontcho Jelev Ph.D. Research Collaborator
Wei Li Postdoctoral Fellow (Visiting)
John Owens Special Volunteer
Yanping Wang Research Collaborator
Tianlei Ying Ph.D. Postdoctoral Fellow (Visiting)
Zhongyu Zhu, Ph.D. Staff Scientist